Read twice and referred to the Committee on Finance.
The bill creates two new federal tax incentives to encourage U.S. production of approved generic drugs and licensed biosimilars. It establishes a production credit (section 45BB) based on value added, with base rates, a domestic-content bonus, exclusions, and a phaseout through 2033.
Liberals emphasize access and demand affordability safeguards.
Relative to its intended legislative type, this bill is a well-specified statutory package creating new tax incentives to promote domestic production of generic drugs and biosimilars.
The bill creates two new federal tax incentives to encourage U.S. production of approved generic drugs and licensed biosimilars.
It establishes a production credit (section 45BB) based on value added, with base rates, a domestic-content bonus, exclusions, and a phaseout through 2033.
It also creates an investment credit (section 48F) equal to 25% of qualifying facility investment, with eligibility, timing limits, and rulemaking authority.
Substantive but narrowly targeted incentives increase plausibility, yet fiscal cost, ideological objections to subsidies, and Senate procedural barriers reduce likelihood.
Relative to its intended legislative type, this bill is a well-specified statutory package creating new tax incentives to promote domestic production of generic drugs and biosimilars. It contains detailed credit formulas, eligibility definitions, exclusions, phaseout schedules, and numerous conforming amendments to the Internal Revenue Code, and it integrates closely with existing tax and regulatory law.
Liberals emphasize access and demand affordability safeguards.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize access and demand affordability safeguards.
Generally supportive because the bill promotes domestic production of affordable generics and biosimilars and addresses supply security.
Concerned that generous tax breaks could become windfalls for large firms absent price or access conditions.
Will favor stronger accountability, transparency, and public-interest safeguards.
Cautious approval: sees practical value in supply chain resilience and jobs.
Wants clearer guardrails to limit waste, prevent fraud, and measure effectiveness.
Prefers oversight, sunset reviews, and documentation rules to reduce unintended costs.
Generally favorable to boosting U.S. manufacturing and reducing foreign dependency, especially for national security.
Skeptical of targeted tax credits as corporate welfare and concerned about long-term fiscal impact and regulatory complexity.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantive but narrowly targeted incentives increase plausibility, yet fiscal cost, ideological objections to subsidies, and Senate procedural barriers reduce likelihood.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize access and demand affordability safeguards.
Substantive but narrowly targeted incentives increase plausibility, yet fiscal cost, ideological objections to subsidies, and Senate proced…
Relative to its intended legislative type, this bill is a well-specified statutory package creating new tax incentives to promote domestic production of generic drugs and biosimilars. It contains detailed credit formula…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.